Inhibition of the AMPK/nNOS pathway for neuroprotection in stroke

• 作 者: Mushfiquddin Khan Inderjit Singh
• 机 构: Department of Pediatrics,Medical University of South Carolina,
• 出 处: Neural Regeneration Research
• 发表日期: 2016年03期
• 关键词: AMPK disability annually nNOS thrombolysis ranks neuronal mortality plasminogen

Stroke ranks fourth among all causes of death and is the major cause of long-term disability in the United States.Furthermore,it is associated with significant morbidity/mortality and a direct/indirect cost of approximately$65 billion annually(Roger et al.,2012).Other than thrombolysis by tissue plasminogen activator(t PA),which offers only a short window of treatment(~3–4 hours),an effective neuroprotective or functional recovery therapy is not available mainly because of

Stroke ranks fourth among all causes of death and is the major cause of long-term disability in the United States. Stillrther, it is associated with significant morbidity / mortality and a direct / indirect cost of approximately $ 65 billion annually (Roger et al. 2012). Of than than thrombolysis by tissue plasminogen activator (t PA), which offers only a short window of treatment (~ 3-4 hours), an effective neuroprotective or functional recovery therapy is not available because of